|
|
 |
|
|
2011Publications
Increasing diversity in pediatric hematology/oncology.
Frugé E, Lakoski JM, Luban N, Lipton JM, Poplack DG, Hagey A, Felgenhauer J, Hilden J, Margolin J, Vaiselbuh SR, Sakamoto KM.
Pediatr Blood Cancer. 2011 Jan 31. doi: 10.1002/pbc.22977. [Epub ahead of print] No abstract available.
PMID: 21284078 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21284078
The multi-targeted receptor tyrosine kinase inhibitor, Linifanib (ABT-869), induces apoptosis through an AKT and Glycogen Synthase Kinase 3{beta}-dependent pathway.
Hernandez-Davies JE, Zape JP, Landaw EM, Tan X, Presnell A, Griffith DJ, Heinrich MC, Glaser KB, Sakamoto KM.
Mol Cancer Ther. 2011 Apr 6. [Epub ahead of print]
|
2010Publications
Self-Renewal of Acute Lymphocytic Leukemia Cells Is Limited by the Hedgehog Pathway Inhibitors Cyclopamine and IPI-926.
Lin TL, Wang QH, Brown P, Peacock C, Merchant AA, Brennan S, Jones E, McGovern K, Watkins DN, Sakamoto KM, Matsui W.
PLoS One. 2010 Dec 28;5(12):e15262.
Ribosomal protein L11 mutation in zebrafish leads to haematopoietic and metabolic defects.
Danilova N, Sakamoto KM, Lin S.
Br J Haematol. 2011 Jan;152(2):217-28. doi: 10.1111/j.1365-2141.2010.08396.x. Epub 2010 Nov 29.
The role of the transcription factor CREB in immune function.
Wen AY, Sakamoto KM, Miller LS.
J Immunol. 2010 Dec 1;185(11):6413-9. Review.
The role of HDAC6 in cancer.
Aldana-Masangkay GI, Sakamoto KM.
J Biomed Biotechnol. 2011;2011:875824. Epub 2010 Nov 7.
Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.
Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, Bunda S, Finklestein JZ, Sakamoto KM, Gorr TA, Mehta P, Schmid I, Kropshofer G, Corbacioglu S, Lang PJ, Klein C, Schlegel PG, Heinzmann A, Schneider M, Starý J, van den Heuvel-Eibrink MM, Hasle H, Locatelli F, Sakai D, Archambeault S, Chen L, Russell RC, Sybingco SS, Ohh M, Braun BS, Flotho C, Loh ML.
Nat Genet. 2010 Sep;42(9):794-800. Epub 2010 Aug 8.
Macroautophagy modulates cellular response to proteasome inhibitors in cancer therapy.
Wu WK, Sakamoto KM, Milani M, Aldana-Masankgay G, Fan D, Wu K, Lee CW, Cho CH, Yu J, Sung JJ.
Drug Resist Updat. 2010 Jun;13(3):87-92
Targeting CREB for cancer therapy: friend or foe.
Xiao X, Li BX, Mitton B, Ikeda A, Sakamoto KM.
Curr Cancer Drug Targets. 2010 Jun;10(4):384-91.
ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways.
Ikeda AK, Judelson DR, Federman N, Glaser KB, Landaw EM, Denny CT, Sakamoto KM.
Mol Cancer Ther. 2010 Mar;9(3):653-60. Epub 2010 Mar 2.
Protacs for treatment of cancer.
Sakamoto KM.
Pediatr Res. 2010 May;67(5):505-8.
|
2008Publications
Cheng JC, Kinjo K, Wu WS, Schmid I, Shankar DB, Stripecke R, Kasahara N, Bhatia R, Landaw EM, and KM Sakamoto. CREB is a critical regulator of normal hematopoiesis and leukemogenesis, Blood, 111: 1182-1192, 2008.
Danilova N, Sakamoto KM, and S Lin. Ribosomal protein S19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family. Blood, Epub May 30, 112(13):5228-37, 2008.
Pellegrini M, Cheng JC, Voutila J, Judelson D, Taylor JA, Nelson SF, and KM Sakamoto. Expression Profile of CREB knockdown in Myeloid Leukemia Cells. BMC Cancer, 18;8:264, 2008 [Epub].
Rodriguez-Gonzalez A, Cyrus K, Salcius M, Kim KB, Crews CM, Deshaies RJ, and KM Sakamoto. Targeting Steroid Hormone Receptors for Ubiquitination and Degradation in Breast and Prostate Cancer, Oncogene, 27:7201-11, 2008.
|
2007Publications
Shankar DB, Li J, Tapang P, McCall JO, Pease LJ, Dai Y, Wei RQ, Albert DH, Hartandi K, Michaelides M, Davidsen SK, Priceman S, Chang J, Shah N, Moore TB, Sakamoto KM*, and KB Glaser. ABT-869 a Multi-Targeted Receptor Tyrosine Kinase Inhibitor: Inhibition of FLT3 Phosphorylation and Signaling in AML, Blood, 109(8):3400-8, 2007. (*co-senior author)
Esparza S, Chang J, Shankar D, Zhang B, Nelson S, and KM Sakamoto. CREB regulates Meis1 Expression in Normal and Malignant Hematopoietic Cells, Leukemia, Sept. 6, 2007.
|
2005Publications
Shankar D, Cheng JC, Kinjo K, Wang J, Federman N, Moore TB, Gill A, Rao N, Landaw EM, and KM Sakamoto. The role of CREB as a proto-oncogene in Hematopoiesis and in Acute Myeloid Leukemia. Cancer Cell, 7:351-362, 2005.
Sakamoto KM. Chimeric Molecules to Target Proteins for Ubiquitination and Degradation. Methods in Enzymology (Ubiquitin and Proteasome System) 299C: 833-837, 2005.
|
2004Publications
Verma R, Peters NR, D'Onofrio, Tochtrop G, Sakamoto KM, Varada R, Fushman D, Deshaies RJ, and RW King. Ubistatins Inhibit Proteasome-Dependent Degradation by Binding the Ubiquitin Chain. Science, 306:117-120, 2004.
Cheng JC and KM Sakamoto. The Emerging Role of RNA Interference in the Design of Novel Therapeutics in Oncology, Cell Cycle, 15: 3-13, 2004.
|
2001Publications
Shou W, Sakamoto KM, Keener J, Morimoto KW, Hoppe GJ, Azzam R, Traverso EE, Feldman RFR, DeModena J, Charbonneau H, Moazed D, Nomura M and RJ Deshaies. RENT complex stimulates RNA Pol I transcription and regulates nucleolar structure independently of controlling mitotic exit. Mol Cell, 8: 45-55, 2001.
Sakamoto KM, Crews CC, Kim KB, Kumagai A, Mercurio F, and RJ Deshaies. Protac: A Chimeric Molecule that targets Proteins to the SCF for Ubiquitination and Degradation. Proc Natl Acad Sci USA, 98: 8554-8559, 2001. |
1991 - 1995Publications
Sakamoto KM, Fraser JK, Lee H-J J, Lehman E, Gasson JC: GM-CSF and IL-3 signaling pathways converge on the CREB-binding site in the human EGR-1 promoter. Mol Cell Biol, 14: 5920-5928, 1994.
Lee H-J J, Mignacca RM, and KM Sakamoto. Transcriptional activation of egr-1 by Granulocyte-Macrophage Colony-Stimulating Factor but not Interleukin-3 requires phosphorylation of CREB on Serine 133. J. Biol. Chem., 270: 15979-15983, 1995.
Wong A and KM Sakamoto. GM-CSF-Induces the Transcriptional Activation of Egr-1 Through a Protein Kinase A-Independent Signaling Pathway. J Biol Chem 270: 30271-30273, 1995.
|
|
|
|
